PRCT

PROCEPT BioRobotics (PRCT) is expected to report Q3 2026 earnings on November 4, with a projected loss of $0.39 per share but revenues up 20.1% year-over-year to $100.07 million. The company has a positive Earnings ESP of +9.79% combined with a Zacks Rank #3 (Hold), suggesting a likely earnings beat. However, the company has only beaten consensus estimates once in the last four quarters.

Grabar Law Office has launched multiple shareholder investigations into four public companies for alleged securities fraud and breach of fiduciary duties. Erasca is accused of making misleading statements about its ERAS-0015 drug candidate and failing to disclose patent infringement risks from Revolution Medicines.

Planet Fitness faces allegations of false marketing claims and concealing declining customer acquisition metrics. PROCEPT BioRobotics is investigated for undisclosed discount programs that artificially inflated sales figures and created excess inventory. The Simply Good Foods Company is accused of failing to disclose operational failures and margin erosion related to its OWYN acquisition.